Death

NEURELIS, INC., NAMED TO LIST OF BEST PLACES TO WORK IN SoCAL 2022

Retrieved on: 
Thursday, August 18, 2022 - 9:15pm
Drug, Diazepam, Schizophrenia, Behavior, Research, Contraindication, Live Company Group, Patient, AND, Central nervous system disease, Human resources, Southern California, Epilepsy, Somnolence, Glaucoma, ROCK, Food, Benzodiazepine, CIV, Anticonvulsant, Multimedia, Risk, CNS, Schedule, Technology, SAN, Seizure, Boxed warning, Science, Intraocular pressure, Woman, Death, Regulation of tobacco by the U.S. Food and Drug Administration, BCG, Coma, Headache, CCMS, Music of Asia, AED, FDA, Depression, Benzyl alcohol, Status epilepticus, Workforce, Health, Hypoventilation, The Last Best Place, Company, View, Therapy, Central nervous system, Metabolic acidosis, Hemangioma, Mania, Suicidal ideation, Adult, Pharmaceutical industry, Management, Dietary supplement, Birth control, Medicine, Gustav Neuring

SAN DIEGO, Aug. 18, 2022 /PRNewswire/ -- Neurelis, Inc., is pleased to announce it has been named one of the Best Places to Work in SoCal 2022 by Best Companies Group (BCG), a BridgeTower Media Company.

Key Points: 
  • SAN DIEGO, Aug. 18, 2022 /PRNewswire/ -- Neurelis, Inc., is pleased to announce it has been named one of the Best Places to Work in SoCal 2022 by Best Companies Group (BCG), a BridgeTower Media Company.
  • "Being named to this list is an incredible honor for all of us," said Neurelis Chief Executive Officer Craig Chambliss.
  • BCG's annual award program identifies and honors the best places to work in Southern California.
  • "Southern California is known for innovation, and the companies that made our Best Places to Work SoCal list take a forward-looking approach to create workplaces of excellence," said Jaime Raul Zepeda, Executive Vice President of Best Companies Group.

Global Digital Pathology Market to Surpass US$ 1,207.8 Million by 2030 - Coherent Market Insights

Retrieved on: 
Thursday, August 18, 2022 - 6:30pm
Cloud computing, Hospital, Death, Diagnosis, Technology, Growth, Cancer, Leica Biosystems, Hamamatsu Photonics, GE Healthcare, Prevalence, Catholic University of Korea, Analysis, Catholic Medical Center, NCI, Infection, Key, CAGR, Pathology, National Cancer Institute, CMC, Medical imaging

SEATTLE, Aug. 18, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global digital pathology market is estimated to be valued at US$ 666.0 million in 2022 and is expected to exhibit a CAGR of 7.7% during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, Aug. 18, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global digital pathology market is estimated to be valued at US$ 666.0 million in 2022 and is expected to exhibit a CAGR of 7.7% during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Digital Pathology Market:
    Integration of cloud computing with digital pathology is also expected to boost growth of the market over the forecast period.
  • The global digital pathology market is expected to exhibit a CAGR of 7.7% during the forecast period due to the Key players in the market are focused on raising funds to expand their product portfolio.
  • Key players operating in the global digital pathology market include Perkin Elmer, Inc., Definiens AG, Sectra ABss, Koninklijke Philips N.V., Paige, GE Healthcare, Inspirata Co.,Ventana Medical Systems, Inc., Leica Biosystems, 3D-Histech Ltd., and Hamamatsu Photonics, K.K.

Global Digital Pathology Market to Surpass US$ 1,207.8 Million by 2030 - Coherent Market Insights

Retrieved on: 
Thursday, August 18, 2022 - 6:30pm
Cloud computing, Hospital, Death, Diagnosis, Technology, Growth, Cancer, Leica Biosystems, Hamamatsu Photonics, GE Healthcare, Prevalence, Catholic University of Korea, Analysis, Catholic Medical Center, NCI, Infection, Key, CAGR, Pathology, National Cancer Institute, CMC, Medical imaging

SEATTLE, Aug. 18, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global digital pathology market is estimated to be valued at US$ 666.0 million in 2022 and is expected to exhibit a CAGR of 7.7% during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, Aug. 18, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global digital pathology market is estimated to be valued at US$ 666.0 million in 2022 and is expected to exhibit a CAGR of 7.7% during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Digital Pathology Market:
    Integration of cloud computing with digital pathology is also expected to boost growth of the market over the forecast period.
  • The global digital pathology market is expected to exhibit a CAGR of 7.7% during the forecast period due to the Key players in the market are focused on raising funds to expand their product portfolio.
  • Key players operating in the global digital pathology market include Perkin Elmer, Inc., Definiens AG, Sectra ABss, Koninklijke Philips N.V., Paige, GE Healthcare, Inspirata Co.,Ventana Medical Systems, Inc., Leica Biosystems, 3D-Histech Ltd., and Hamamatsu Photonics, K.K.

U.S. on track to break record for the most products recalled in a single year

Retrieved on: 
Thursday, August 18, 2022 - 6:00pm
FDA, Death, National Highway Traffic Safety Administration, Monkeypox, Multimedia, Onex, Industry, The Carlyle Group, Face, United States Department of Agriculture, NHTSA, Sale, Compliance, Infant, COVID-19, Food, USDA, View, Cannabis, Menthol, Safety, CDPQ, Food and Drug Administration, PFAS, Health, Organization, Medical device, Pharmaceutical industry, Risk management, Q2

MEMPHIS, Tenn., Aug. 18, 2022 /PRNewswire/ -- The number of U.S. products recalled this year has already surpassed 1 billion, according to the U.S. product recall index recently released by Sedgwick's brand protection division. Only two other years on record have seen more than 1 billion units recalled: 2018 and 2021. In those years, it took a full year to hit that threshold. In 2022, it only took the first seven months of the year, setting this up to be a record-breaking year for product recalls by number of units.

Key Points: 
  • Only two other years on record have seen more than 1 billion units recalled: 2018 and 2021.
  • The number of consumer product recalls decreased 15.6% in Q2 2022 from 77 events in Q1 to 65.
  • The total number of units recalled also decreased in Q2, but by only 3.5% to 6.7 million units.
  • U.S. Department of Agriculture (USDA) food recalls increased to their highest level in more than two years, with 13 events.

Experienced Attorneys at Dallas' Law Offices of Brad Jackson Again Ranked Among Nation's Best for Business Lawsuits

Retrieved on: 
Thursday, August 18, 2022 - 4:30pm
Death, Damages, Spectrum, Hearing, Texas Board of Legal Specialization, Personal injury, Charter Communications, Law, History, People's Law Office, Life, Charter Spectrum, Property management, Online gambling

The verdict handed down in late July is one of the five largest jury awards in U.S. history.

Key Points: 
  • The verdict handed down in late July is one of the five largest jury awards in U.S. history.
  • Based in Dallas, The Law Offices of Brad Jackson provides decades of experience representing clients in Texas and across the nation.
  • Brad Jackson is Board Certified in Civil Trial Law by the Texas Board of Legal Specialization.
  • The firm handles practically every type of business dispute, as well as cases involving serious personal injury and wrongful death.

Colorectal Cancer Market Report 2022-2028: Increasing Prevalence of Colorectal Cancer & Benefits Offered by Generic Drugs to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022 - 3:45pm
Pharmaceutical, Health, Oncology, Death, Modality, CRC, 40, Growth, India Brand Equity Foundation, Feces, Prevalence, Medical tourism, Insurance, Blood, Patient, CEA, COVID-19, Colorectal cancer, Vaccine, Colonoscopy, CAGR, Pressure, Immunohistochemistry, FOBT, Australian Institute of Health and Welfare, Pharmaceutical industry, Medical imaging

The global colorectal cancer market is expected to grow from US$ 18,619.3 million in 2022 to US$ 24,078.5 million by 2028.

Key Points: 
  • The global colorectal cancer market is expected to grow from US$ 18,619.3 million in 2022 to US$ 24,078.5 million by 2028.
  • Factors such as the increasing prevalence of colorectal cancer, product launches, and benefits offered by generic drugs are driving the growth of the global colorectal cancer market.
  • However, pricing pressure on drug manufacturers is hampering the global colorectal cancer market growth.
  • The increasing medical tourism and the growing pharmaceutical industry in emerging countries are expected to boost the global colorectal cancer market growth.

Parsemus Foundation: Metformin Drastically Reduces COVID Hospitalization, Study Shows

Retrieved on: 
Thursday, August 18, 2022 - 3:38pm
Health, Consumer, Diabetes, Infectious Diseases, Clinical Trials, Pharmaceutical, Hispanic, Parsemus Foundation, Â, The New England Journal of Medicine, Lissner, University, Inflammation, Metformin, Death, Assistant, COVID, Research, COVID-19, Foundation, MTOR, Solution, Fluvoxamine, Health, Pharmaceutical industry, Hospital

The results were published Aug. 18 in the New England Journal of Medicine, according to Parsemus Foundation.

Key Points: 
  • The results were published Aug. 18 in the New England Journal of Medicine, according to Parsemus Foundation.
  • But you dont know whether its just coincidence until you go back to the beginning, with a rigorous randomized trial.
  • Parsemus Foundation was joined by two larger foundations also eager to see low-cost, globally-accessible medications put to the test.
  • More information on the Parsemus Foundation and the work presented here can be found at: https://www.parsemus.org/humanhealth/covid-19/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005438/en/

Chicken Salad Chick Launches 'Cookies for a CURE' to Raise Money for Childhood Cancer Research

Retrieved on: 
Thursday, August 18, 2022 - 3:59pm
Death, Movers and Shakers, CEO, Chicken Salad Chick, Growth, Cancer, Leadership, Childhood cancer, QSR, Research, CLIC Sargent, Restaurant, Patient, CURE, Partnership, Awareness, Franchise Times, Chicken salad, CSC, Gold, Heart, Vaccine, Fast food, Pharmaceutical industry

ATLANTA, Aug. 18, 2022 /PRNewswire/ -- Chicken Salad Chick, the nation's only fast-casual chicken salad restaurant concept, announced today the launch of its Cookies for a CURE promotion as part of a nationwide initiative to raise money and support pediatric cancer research. Beginning September 5, Chicken Salad Chick will be selling new Lemon Burst Buttercream Cookies at all participating locations. Chicken Salad Chick will donate a portion of the proceeds from Cookies for a CURE directly to their partner organization, CURE Childhood Cancer, whose mission is dedicated to childhood cancer research while supporting patients and their families.

Key Points: 
  • Promotion will take place in September in Honor of Childhood Cancer Awareness Month; Proceeds will Fund Childhood Cancer Research Through the Chicken Salad Chick Foundation
    ATLANTA, Aug. 18, 2022 /PRNewswire/ -- Chicken Salad Chick , the nation's only fast-casual chicken salad restaurant concept, announced today the launch of its Cookies for a CURE promotion as part of a nationwide initiative to raise money and support pediatric cancer research.
  • Chicken Salad Chick will donate a portion of the proceeds from Cookies for a CURE directly to their partner organization, CURE Childhood Cancer, whose mission is dedicated to childhood cancer research while supporting patients and their families.
  • "With the support from our partnership with Chicken Salad Chick and their generosity, we were able to set a record this year with grants for childhood cancer research totaling more than $4.7 million," said Kristin Connor, CEO of CURE Childhood Cancer.
  • Chicken Salad Chick serves full-flavored, Southern-style chicken salad made from scratch and served from the heart.

New Product Safety Recalls

Retrieved on: 
Thursday, August 18, 2022 - 3:22pm
Death, Commission, CPSC, Risk, Injury, Safety, U.S. Consumer Product Safety Commission, Insurance, Medical device, Dietary supplement

The U.S. Consumer Product Safety Commission (CPSC) is charged with protecting the public from unreasonable risk of injury or death associated with the use of thousands of types of consumer products.

Key Points: 
  • The U.S. Consumer Product Safety Commission (CPSC) is charged with protecting the public from unreasonable risk of injury or death associated with the use of thousands of types of consumer products.
  • Deaths, injuries, and property damage from consumer product-related incidents cost the nation more than $1 trillion annually.
  • CPSC's work to ensure the safety of consumer products has contributed to a decline in the rate of injuries associated with consumer products over the past 50 years.
  • Federal law prohibits any person from selling products subject to a Commission ordered recall or a voluntary recall undertaken in consultation with the CPSC.

Trustate Unveils First-of-its-kind Asset and Liability Tool for Trusts and Estates Professionals

Retrieved on: 
Thursday, August 18, 2022 - 3:00pm
Death, API, CEO, Technology, SVP, Learning, Humble (production studio), Equifax, Instagram, Program, Partnership, COO, Trusts & Estates (journal), Solution, Time, LinkedIn, Property management, Real estate, Facebook

TAMPA, Fla., Aug. 18, 2022 /PRNewswire-PRWeb/ -- Trustate, the award-winning, female-founded Tampa Bay estate administration startup that uses technology to seamlessly administer estates, today announces the launch of a first-of-its-kind asset and liability decedent discovery tool. The solution is designed to give trusts and estates professionals the accurate and real-time data they need to effectively administer an estate. This launch comes six months after the estate administration disruptor announced an oversubscribed fundraising round led by the international fintech investment firm, Impression Ventures.

Key Points: 
  • TAMPA, Fla., Aug. 18, 2022 /PRNewswire-PRWeb/ -- Trustate , the award-winning, female-founded Tampa Bay estate administration startup that uses technology to seamlessly administer estates, today announces the launch of a first-of-its-kind asset and liability decedent discovery tool.
  • The solution is designed to give trusts and estates professionals the accurate and real-time data they need to effectively administer an estate.
  • Incorrect information or overlooking assets and liabilities can not only open estates professionals to liability but can also extend an already time-consuming and emotional process.
  • Trustate is the nation's leading estate administration technology created to ease the burden of estate administration for trusts and estates professionals and the clients they serve.